Juan Francisco Zazueta Pozos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Juan Francisco Zazueta Pozos has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Martínez-Murillo
Hematology Department, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City P.C. 06720, Mexico
2 shared publications - Christian Omar Ramos Peñafiel
Hospital General de México, México
2 shared publications - Gilberto Barranco
Departamento de Hematología Hospital Central Militar Mexico City
2 shared publications - Adán Germán Gallardo Rodríguez
School of Sport Sciences, Universidad Anáhuac México
1 shared publication - Alonso Hernández Company1 shared publication
Beatriz Li Gómez
Hematology Department of Hospital General de México, Dr Eduardo Liceaga México City Mexico
1 shared publication
Latest Publications
- Open Access
- 2 April 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (2)
Essential role of radiotherapy in NK/T-cell lymphoma: evidence from a single-center study in Mexico
- 2 April 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (2)
Open AccessEssential role of radiotherapy in NK/T-cell lymphoma: evidence from a single-center study in Mexico
- Open Access
- 14 June 2021
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 4 (3) , e00279
COVID‐19 in a country with a very high prevalence of diabetes: The impact of admission hyperglycaemia on mortality
Aims: To evaluate the frequency of diabetes and admission hyperglycaemia in Mexican COVID‐19 patients, to describe the clinical and biochemical characteristics of patients with admission hyperglycaemia and to determinate the impact of diabetes and admission hyperglycaemia on COVID‐19 severity and mortality.Methods: A multicentric study was performed in 480 hospitalized patients with COVID‐19. Clinical and biochemical characteristics were evaluated in patients with admission hyperglycaemia and compared with non‐hyperglycaemic patients. The effect of diabetes and admission hyperglycaemia on severity and risk of death were evaluated.Results: Age was 50.7 ± 13.6 years; 68.3% were male. Some 48.5% (n = 233) had admission hyperglycaemia; 29% (n = 139) of these patients had pre‐existing diabetes. Patients with admission hyperglycaemia had more requirement of invasive mechanical ventilation (IMV), higher levels of urea, D‐dimer and neutrophil‐lymphocyte ratio (NLR), as well as lower lymphocyte count. An association between admission hyperglycaemia with IMV and D‐dimer with glucose was found. Age ≥50 years (OR 2.09; 95%CI 1.37–3.17), pre‐existing diabetes (OR 2.38; 95%CI 1.59–5.04) and admission hyperglycaemia (OR 8.24; 95%CI 4.74–14.32) were risk factors for mortality.Conclusions: Admission hyperglycaemia is presented in 48.5% of COVID‐19 patients. Diabetes and admission hyperglycaemia are associated with the severity of disease and mortality. This study shows the devastating conjunction of hyperglycaemia and COVID‐19.Clinical trial registration: Clinical characteristics of patients with COVID‐19, DI/20/204/04/41 (Hospital General de Mexico) and NR‐13‐2020 (Hospital Regional de Alta Especialidad Ixtapaluca).
- 14 June 2021
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 4 (3) , e00279
Open AccessCOVID‐19 in a country with a very high prevalence of diabetes: The impact of admission hyperglycaemia on mortality
Aims: To evaluate the frequency of diabetes and admission hyperglycaemia in Mexican COVID‐19 patients, to describe the clinical and biochemical characteristics of patients with admission hyperglycaemia and to determinate the impact of diabetes and admission hyperglycaemia on COVID‐19 severity and mortality.Methods: A multicentric study was performed in 480 hospitalized patients with COVID‐19. Clinical and biochemical characteristics were evaluated in patients with admission hyperglycaemia and compared with non‐hyperglycaemic patients. The effect of diabetes and admission hyperglycaemia on severity and risk of death were evaluated.Results: Age was 50.7 ± 13.6 years; 68.3% were male. Some 48.5% (n = 233) had admission hyperglycaemia; 29% (n = 139) of these patients had pre‐existing diabetes. Patients with admission hyperglycaemia had more requirement of invasive mechanical ventilation (IMV), higher levels of urea, D‐dimer and neutrophil‐lymphocyte ratio (NLR), as well as lower lymphocyte count. An association between admission hyperglycaemia with IMV and D‐dimer with glucose was found. Age ≥50 years (OR 2.09; 95%CI 1.37–3.17), pre‐existing diabetes (OR 2.38; 95%CI 1.59–5.04) and admission hyperglycaemia (OR 8.24; 95%CI 4.74–14.32) were risk factors for mortality.Conclusions: Admission hyperglycaemia is presented in 48.5% of COVID‐19 patients. Diabetes and admission hyperglycaemia are associated with the severity of disease and mortality. This study shows the devastating conjunction of hyperglycaemia and COVID‐19.Clinical trial registration: Clinical characteristics of patients with COVID‐19, DI/20/204/04/41 (Hospital General de Mexico) and NR‐13‐2020 (Hospital Regional de Alta Especialidad Ixtapaluca).